Compare SBCF & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBCF | BEAM |
|---|---|---|
| Founded | 1926 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.0B |
| IPO Year | 2009 | 2019 |
| Metric | SBCF | BEAM |
|---|---|---|
| Price | $33.22 | $26.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $38.00 | ★ $50.75 |
| AVG Volume (30 Days) | 1.2M | ★ 2.7M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | 10.56 | ★ 82.31 |
| EPS | ★ 0.29 | N/A |
| Revenue | N/A | ★ $24,000.00 |
| Revenue This Year | $45.04 | N/A |
| Revenue Next Year | $6.30 | $33.77 |
| P/E Ratio | $115.10 | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $27.22 | $15.60 |
| 52 Week High | $35.55 | $38.26 |
| Indicator | SBCF | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 54.85 | 33.67 |
| Support Level | $32.82 | $24.80 |
| Resistance Level | $35.50 | $29.99 |
| Average True Range (ATR) | 0.78 | 2.21 |
| MACD | -0.02 | -1.00 |
| Stochastic Oscillator | 52.73 | 4.11 |
Seacoast Banking Corp of Florida is a holding company. The company provides integrated financial services, including commercial and consumer banking, wealth management, and mortgage and insurance services, to customers across Florida through branch, mobile, and online banking solutions. It maintains day-to-day operations, particularly in the areas of operations, treasury management systems, information technology, and security. The company has one reportable segment that provides these integrated financial services, with segment revenues driven mainly by interest and fees on loans, interest on cash and cash equivalents, and investment securities, and fees on depository products and services.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.